Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist Kayode OgungbenroSharon HulmeJames Galea Original Paper 18 October 2015 Pages: 1 - 12
Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment Sophie PeignéFrançois BouzomMarylore Chenel Original Paper 12 November 2015 Pages: 13 - 27
Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment Sophie PeignéSylvain FouliardMarylore Chenel Original Paper 14 November 2015 Pages: 29 - 43
Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis Chuanpu HuHonghui Zhou Original Paper 09 November 2015 Pages: 45 - 54
Erratum to: Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis Chuanpu HuHonghui Zhou Erratum 23 November 2015 Pages: 55 - 55
Application of a hazard-based visual predictive check to evaluate parametric hazard models Yeamin HuhMatthew M. Hutmacher Original Paper 13 November 2015 Pages: 57 - 71
Population pharmacokinetics of ramosetron Seong Heon LeeSoo Young ChoSeongwook Jeong Original Paper 11 November 2015 Pages: 73 - 83
Stochastic nonlinear mixed effects: a metformin case study Brett MatzukaJason ChittendenHien Tran Original Paper 19 November 2015 Pages: 85 - 98
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation Ayman AkilRobert R. BiesConstantine G. Lyketsos Original Paper Open access 26 November 2015 Pages: 99 - 109
What do we mean by identifiability in mixed effects models? Marc LavielleLeon Aarons Original Paper 10 December 2015 Pages: 111 - 122